Evidence map›Paper›PMID 36313211›Full record

ArticleAmerican journal of clinical and experimental urology2022

PD1.5 variant on

Gabriela Vilas Bôas Gomez, Larissa Nara Alegrini Longhi, Helena Paes Almeida Saito, Gustavo Jacob Lourenço, Rodolfo Borges Dos Reis, Marcos Tobias Machado, Leonardo Oliveira Reis, Fernandes Denardi, Carmen Silvia Passos Lima

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabriela Vilas Bôas GomezLaboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.
Larissa Nara Alegrini LonghiLaboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.
Helena Paes Almeida SaitoLaboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.
Gustavo Jacob LourençoLaboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.
Rodolfo Borges Dos ReisDepartment of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo Ribeirão Preto, São Paulo, Brazil.
Marcos Tobias MachadoDepartment of Urooncology, Faculty of Medicine ABC Santo André, São Paulo, Brazil.
Leonardo Oliveira ReisUroScience Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.
Fernandes DenardiDepartment of Surgery, Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.
Carmen Silvia Passos LimaLaboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince failure in recognition of abnormal cells by the immune system has an important role in bladder cancer development and progression, this study aimed to evaluate whether PD1 (c.627+252C>T) and PD1.5 (c.804C>T) single-nucleotide variants (SNVs) in MATERIAL AND

methodsDNA genotyping by real-time polymerase chain reaction was offered to 160 non muscle invasive bladder cancer (NMIBC) patients and 250 controls. One hundred and twenty-seven patients treated with bladder transurethral resection and intravesical bacillus Calmette-Guérin were enrolled in survival analyses.

resultsIndividuals with PD1.5 CC genotype had 2.3-fold increased risk of developing NMIBC. Similar genotype and haplotype frequencies were seen in patients stratified by clinicopathological aspects. Patients with T allele, CT or TT plus CT or TT genotype and TT haplotype of PD1 and PD1.5 SNVs had up to 4.0-times greater chances of presenting NMIBC relapse and death by any cause than the remaining patients, but analysis of NMIBC specific survival was not possible in study due to the small number of patients evolving to death during follow up.

conclusionsOur data presented for the first time, preliminary evidence that inherited abnormality in regulation of T lymphocyte activity alters NMIBC risk.

Indexed as

Bladder cancerPDCD1 geneprognosisrisksingle-nucleotide variant

Identifiers

PMID36313211
PMCPMC9605939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.